Results 51 to 60 of about 272,512 (195)
MYCN Gene Copy Number Status Detected by FISH Method and Its Correlation with Outcome and Clinicopathological Variables in Childhood Neuroblastoma [PDF]
Middle East Journal of CancerBackground: Neuroblastoma is the most common extracranial solid tumor in children. MYCN gene amplification (MNA) is an independent prognostic factor for rapid tumor progression and poor prognosis, regardless of age and clinical stage.
Mahdi Shahriari +3 more
doaj +1 more source
Journal of International Medical Research, 2018 Objectives Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN is amplified in nearly half of patients with NB, and its association with rapid disease progression and poor outcome is controversial.
Zhi-Yong Zhong +3 more
doaj +1 more source
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma
Nature Communications, 2022 Half of high-risk neuroblastoma patients have MYCN amplification. Here, the authors show that MYCN induces fatty acid uptake and synthesis to support neuroblastoma and inhibition of a fatty acid transporter impairs tumor progression in preclinical models.
Ling Tao +19 more
doaj +1 more source
The potential molecularly therapy target to MYCN‐amplificated neuroblastoma
Clinical and Translational Discovery, 2023 AbstractNeuroblastoma (NB) is an embryonal deadly cancer in childhood driven by MYC or MYCN‐driven oncogenic signaling. The amplification of MYCN leads to malignant progression of NB and poor prognosis. Traditional chemotherapy is still a standard treatment for NB. Most of the cytostatic drugs take function in anti‐neuroblastoma. However, children with
Susu Jiang +5 more
openaire +2 more sources
FEBS Open Bio, EarlyView.Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar +4 more
wiley +1 more source
Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma
Nature Communications, 2020 MYCN amplification is common in neuroblastomas. Here the authors analyse the MYCN amplicon structure and its epigenetic regulation by integrating short- and longread genomic and epigenomic data and find two classes of MYCN amplicons in neuroblastomas ...
Konstantin Helmsauer +28 more
doaj +1 more source
MYCN Function in Neuroblastoma Development
Frontiers in Oncology, 2021 Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of MYCN is a single oncogenic driver inducing neoplastic transformation in neural crest ...
Jörg Otte +3 more
doaj +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
PLoS ONE, 2014 Neuroblastoma (NB) is the most common malignant disease of infancy. MYCN amplification is a prognostic factor for NB and is a sign of highly malignant disease and poor patient prognosis. In this study, we aimed to investigate novel MYCN-related genes and
Pei-Yi Wu +10 more
doaj +1 more source